The product has been added to the cart.
By using our website, you agree to our use of cookies. find out more.
-
Products
Pharmacology
Type
- News
- Custom services
- Ordering
- About Us
- Technical support
- Resources
-
Products
Pharmacology
Type
- News
- Custom services
- Ordering
- About Us
- Technical support
- Resources
Rimonabant
Cat. No. CB-020
Structure:
Other Names:
Activity:
Rimonabant is a selective CB1 receptor inverse agonist with a Ki of 1.8 nM and no activity at CB2 receptors. Rimonobant also acts as a μ-opioid receptor antagonist with a Ki of 652 nM. Rimonabant reduces the overactivity of the endocannabinoid system, improving lipid and glucose metabolism and regulating energy balance. In animal sudies, it reduces food intake and body weight in orally dosed non-obese Wistar rats and has a positive role in reducing hunger, caloric intake, and body weight, and in increasing satiety. In humans, rimonabant initially appeared to be effective for treatment of obesity and smoking cessation but was withdrawn from the market due to having the potential to cause severe psychiatric side effects.
Rinaldi-Carmona et al (1995) Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 56(23-24) 1941 PMID: 7776817
Colombo et al (1998) Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. 63(8) PL113-7 PMID: 9718088
Boyd and Fremming (2005) Rimonabant--a selective CB1 antagonist. Ann Pharmacother. 39(4) 684 PMID: 15755787
Seely et al (2012) AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies. Neuropharmacology 63(5) 905 PMID: 22771770
Bosquez-Berger et al (2023) A. Requiem for Rimonabant: Therapeutic Potential for Cannabinoid CB1 Receptor Antagonists after the Fall. Drugs Drug Candidates 2 689 https://doi.org/10.3390/ddc2030035
Related areas
All small molecules >
All cannabinoid receptor modulators >
All μ opioid receptor modulators >
All neuroscience research categories >
All appetite regulation research categories >
Technical Data
Structure | 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-yl-1H-pyrazole-3-carboxamide |
CAS Number | 168273-06-1 |
Molecular Weight | 463.8 |
Formula | C22H21Cl3N4O |
Solubility and Storage
Solubility | Soluble in DMSO to 20 mg/ml or ethanol to 20 mg/ml |
Appearance | White solid |
Storage | Store dry, frozen and in the dark |
Batch Specific Data
Purity | > 98% by hplc, NMR conforms |
Contact Information
To place an order, or for customer services, order processing or technical support please contact us on:
UK, Europe and RoW
Tel: (+44) 01392 422205
Fax: (+44) 01392 279510
info@iscabiochemicals.com
USA and Canada
Tel: 610-994-1134
Toll Free: 855-FOCUS21 (855-362-8721)
Fax: 610-465-9100
France
CliniSciences
Tel : +33 9 77 40 09 09
Fax : +33 9 77 40 10 11
Orders and customer support : info@clinisciences.com
Germany, Switzerland, Austria
BIOZOL Diagnostics
Tel: +49 (089) 3799 666-6
Fax: +49 (089) 3799 666-99
Orders, Technical and Customer support: info@biozol.de
Italy
Labospace
Tel: +39 02 35980841
Fax +39 02 359808004
Orders: info@labospace.com
Spain and Portugal
Abyntek Biopharma
Tel: +34 94 404 80 80
Fax: +34 94 404 80 81
Orders: info@abyntek.com
BIOHUB INTERNATIONAL
上海起发实验试剂有限公司
Tel: +86-15921799099
Tel: +86-021-50724187
Fax: +86-021-50724961
Orders: sale3@78bio.com
India
BTL Biotechno Labs Pvt Ltd
Tel: +91-8860924629
07291852429
Orders, Technical and Customer support: info@biotechnolabs.com
Japan
Namiki Shoji Co.
Tel:+81-050-5527-9850
Fax:+81-3-3352-2196
email: globalbusiness1@namiki-s.co.jp
Recent citations
A new publication from the University of Ljubljana uses MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2, the FRET substrate for the severe acute respiratory syndrome coronavirus main protease (SARS-CoV Mpro), to determine the inhibitory potential of plant polyphenols
Learn moreContact us
Isca Biochemicals
26 Hanover Road
Exeter
EX1 2TL
(+44) 01392 422205
info@iscabiochemicals.com